Regeneron, Vir pursuing different scientific paths to COVID-19 antibody therapies
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Regeneron and Vir, two of the companies at the forefront of the race to develop antibody-based therapies for COVID-19, have very different ideas about the best ways to discover and develop mAbs that could protect against or treat the disease.
Vir is prioritizing a single antibody against an epitope that is conserved between the coronaviruses that cause COVID-19 and severe acute respiratory syndrome (SARS), while Regeneron is focused on cocktails of antibodies that are specific to COVID-19.
George Yancopoulos, co-founder, president and